REG - Cambridge Cognition - Monument Therapeutics MT1988 First Patient Dosed

Cambridge Cognition HoldingsAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260311:nRSK1140Wa&default-theme=true

RNS Number : 1140W  Cambridge Cognition Holdings PLC  11 March 2026

11 March 2026

 

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

 

Cambridge Cognition Investment, Monument Therapeutics, Announces First Patient
Dosed in Clinical Trial of MT1988 in Patients at Clinical High Risk for
Psychosis

 

Cambridge UK, March 11, 2026 - Cambridge Cognition (AIM: COG), the
neuroscience technology company whose digital cognitive assessments drive
scientific discovery, accelerate drug development and improve patient care,
reports that Monument Therapeutics Limited ("Monument"), in which the Group
has a 20% shareholding, has announced the dosing of the first patient in its
clinical trial with MT1988, to treat patients at clinical high risk (CHR) for
psychosis.

The study is being conducted in collaboration with the Foundation for the
National Institutes of Health (FNIH) as part of the Accelerating Medicines
Partnership® Schizophrenia (AMP® SCZ) program.  This trial marks a major
step forward in developing treatment options for people at risk of
schizophrenia.

The randomised, placebo-controlled, proof-of-principle study will enrol 150
CHR participants who will receive one of two dose levels of MT1988 or placebo
over an eight-week treatment period.  The trial will evaluate the potential
of MT1988 to improve cognitive symptoms in CHR individuals, incorporating a
range of clinical and cognitive biomarkers.  This approach is designed to
assess not only therapeutic effects but also the potential of these biomarkers
to predict and monitor treatment response.

Cambridge Cognition's proprietary digital cognitive assessment technologies
supported the early development of MT1988 and were instrumental in
establishing the foundational biomarker strategy for Monument.

Sheryl Caswell, Chief Development Officer of Monument Therapeutics said
"Dosing our first patient marks a pivotal moment for Monument Therapeutics and
for people at risk of developing psychosis, because, despite the significant
impact of this early stage of illness, there are currently no approved
pharmacological treatments for the CHR population."

Rob Baker, Chief Executive Officer - Cambridge Cognition said, "We
congratulate our colleagues at Monument for achieving this milestone in
MT1988's development. Treatment of the first patient represents a significant
value inflection point for Monument.  We believe using both biological
biomarkers and Cambridge Cognition's digital assessments of cognitive function
to assess MT1988 will provide insights into the underlying biology and also
capture observable changes in cognitive function."

 

NOTES TO EDITORS

 

ABOUT CAMBRIDGE COGNITION AND CANTAB PATHWAY™

Cambridge Cognition is a neuroscience technology company whose digital
cognitive assessments support scientific discovery, accelerate drug
development and improve patient care.

The Company has developed a suite of touchscreen and voice-based cognitive
assessments delivered under the CANTAB and Winterlight brands.  These
assessments are designed to:

●    require minimal specialist administration

●    deliver objective results in real time or shortly after completion

●    reduce administrator bias

●    support longitudinal monitoring of cognitive function

Assessment results can be presented in formats appropriate for both consumers
in home-use settings and healthcare professionals in clinical or research
environments.

CANTAB Pathway™ is Cambridge Cognition's latest scalable cognitive
assessment solution, structured as an escalating series of tasks for use in
consumer and healthcare settings:

●    CANTAB One™ - a brief assessment of overall cognitive function

●    CANTAB Insight™ - a three-task battery providing deeper insight
across five cognitive sub-domains

●    CANTAB Plus™ - specialist disease-specific modules for use by
appropriately qualified healthcare professionals, covering eight indications
including Parkinson's disease, ADHD, multiple sclerosis, Huntington's disease,
schizophrenia, depression, and Alzheimer's disease and related dementias

For further information, visit: www.cambridgecognition.com
(http://www.cambridgecognition.com/)

 

About Monument Therapeutics:

Monument Therapeutics is a neuroscience-focused drug development company
headquartered in Manchester, UK.  It applies a unique and novel drug
development strategy, leveraging digital assessments of cognition to select
patients suitable for treatment with the innovative drugs that it is
developing.

For more information, please visit www.monumenttx.com
(http://www.monumenttx.com/) .

About the Foundation for the National Institutes of Health:

The Foundation for the National Institutes of Health (FNIH) builds
public-private partnerships that connect leading biomedical scientists at the
National Institutes of Health (NIH) with their counterparts in life sciences
companies, academia, patient organizations, foundations, and regulatory
agencies (including the U.S. Food and Drug Administration and European
Medicines Agency).  Through team science, the FNIH solves complex health
challenges and accelerates breakthroughs for patients, regardless of who they
are or what health threats they face.  The FNIH contributes to the
development of new therapies, diagnostics, and potential cures; advances
global health; and helps train the next generations of scientists.
Established by Congress in 1990 to support the mission of the NIH, the FNIH is
a not-for-profit 501(c)(3) charitable organization.  For more information
about the FNIH, please visit fnih.org (https://fnih.org/) .

About the Accelerating Medicines Partnership®:

Launched in 2014 and managed by the FNIH, the Accelerating Medicines
Partnership (AMP) program brings together the National Institutes of Health,
U.S. Food and Drug Administration, biomedical and life sciences companies,
nonprofits, patient-focused groups, and other organizations to transform the
current model for developing new diagnostics and treatments.  Using
cutting-edge scientific approaches and broad sharing of research data, all
AMPs seek to improve understanding of disease pathways, facilitate better
selection of targets for drug development, and streamline processes for
bringing new treatments to patients.  To learn more about AMP,

visit fnih.org/AMP (https://fnih.org/AMP) .

 

Enquiries:

 Cambridge Cognition Holdings plc                    Tel: +44 1223 810700 

 Rob Baker, Chief Executive Officer                  press@camcog.com (mailto:press@camcog.com)  

 Ronald Openshaw, Chief Financial Officer

 Adam Michael, Head of Corporate Communications
 Panmure Liberum Limited (NOMAD & Joint Broker)      Tel: +44 20 7886 2968

 Will Goode / Mark Rogers / Freddy Crossley          (Corporate Finance)

 Rupert Dearden                                      (Corporate Broking)
 Singer Capital Markets Limited (Joint Broker)       Tel: +44 20 7496 3000

 Amber Higgs / James Serjeant / Daniel Ingram         

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCMZGMFNGNGVZM



            Copyright 2019 Regulatory News Service, all rights reserved